Literature DB >> 7697521

Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis.

D M Waag1, K T McKee, G Sandstrom, L L Pratt, C R Bolt, M J England, G O Nelson, J C Williams.   

Abstract

The specific humoral and cell-mediated immune responses of human volunteers vaccinated with the Francisella tularensis live vaccine strain (LVS) were evaluated. In the search for an optimal antigen to measure the immunogenicity of the vaccine in an enzyme-linked immunosorbent assay, we tested irradiation-killed LVS, an aqueous ether extract of the LVS (EEx), lipopolysaccharide (LPS) from LVS, and a virulent strain (SCHU4). Volunteers were immunized with LVS by scarification. Immunoglobulin G (IgG) responses to LVS and LPS gave the highest background titers when tested with sera from unimmunized volunteers, whereas IgA, IgG, and IgM background titers to EEx and SCHU4 were low. Vaccination caused a significant rise (P < 0.01) in IgA, IgG, and IgM titers to all antigens tested, except for the IgG response to LPS. Eighty percent of vaccinated volunteers developed a positive IgG response to EEx 14 days postvaccination, while 50% were positive to LVS. By day 14 after vaccination, 70% of immunized volunteers exhibited a positive response to EEx in an in vitro peripheral blood lymphocyte proliferation assay. EEx, a specific and sensitive antigen for evaluating immune responses of vaccinated volunteers, may be a superior antigen for the diagnosis of tularemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697521      PMCID: PMC170117          DOI: 10.1128/cdli.2.2.143-148.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Microagglutination test for early and specific serodiagnosis of tularemia.

Authors:  T Sato; H Fujita; Y Ohara; M Homma
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

2.  Public Health Weekly Reports for JUNE 25, 1926.

Authors: 
Journal:  Public Health Rep       Date:  1926-06-25       Impact factor: 2.792

3.  Agglutination and ELISA methods in the diagnosis of tularemia in different clinical forms and severities of the disease.

Authors:  H Syrjälä; P Koskela; T Ripatti; A Salminen; E Herva
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  Enzyme-linked immunosorbent assay for immunological diagnosis of human tularemia.

Authors:  H E Carlsson; A A Lindberg; G Lindberg; B Hederstedt; K A Karlsson; B O Agell
Journal:  J Clin Microbiol       Date:  1979-11       Impact factor: 5.948

5.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  Cell-mediated and humoral immunity induced by a live Francisella tularensis vaccine.

Authors:  P Koskela; E Herva
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

7.  Cell-mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis.

Authors:  D M Waag; A Galloway; G Sandstrom; C R Bolt; M J England; G O Nelson; J C Williams
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

8.  A whole-blood lymphocyte stimulation test for the diagnosis of human tularemia.

Authors:  H Syrjälä; E Herva; J Ilonen; K Saukkonen; A Salminen
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

9.  Time of lymphocyte response after onset of tularemia and after tularemia vaccination.

Authors:  A Tärnvik; G Sandström; S Löfgren
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

10.  Immunospecific T-lymphocyte stimulation by membrane proteins from Francisella tularensis.

Authors:  G Sandström; A Tärnvik; H Wolf-Watz
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

View more
  13 in total

1.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

2.  Evaluation of an immunochromatographic test for rapid and reliable serodiagnosis of human tularemia and detection of Francisella tularensis-specific antibodies in sera from different mammalian species.

Authors:  W Splettstoesser; V Guglielmo-Viret; E Seibold; P Thullier
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.

Authors:  David M Waag; Marilyn J England; Christopher R Bolt; Jim C Williams
Journal:  Clin Vaccine Immunol       Date:  2008-08-13

5.  Water-borne outbreak of oropharyngeal and glandular tularemia in Georgia: investigation and follow-up.

Authors:  N Chitadze; T Kuchuloria; D V Clark; E Tsertsvadze; M Chokheli; N Tsertsvadze; N Trapaidze; A Lane; L Bakanidze; S Tsanava; M J Hepburn; P Imnadze
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

Review 6.  Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.

Authors:  Girish S Kirimanjeswara; Sofia Olmos; Chandra S Bakshi; Dennis W Metzger
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

7.  Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy.

Authors:  Roberto De Pascalis; Lara Mittereder; Nikki J Kennett; Karen L Elkins
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

8.  Immunity to Francisella.

Authors:  Siobhán C Cowley; Karen L Elkins
Journal:  Front Microbiol       Date:  2011-02-16       Impact factor: 5.640

9.  The francisella tularensis proteome and its recognition by antibodies.

Authors:  Sara L N Kilmury; Susan M Twine
Journal:  Front Microbiol       Date:  2011-01-07       Impact factor: 5.640

10.  Identification of a live attenuated vaccine candidate for tularemia prophylaxis.

Authors:  Manish Mahawar; Seham M Rabadi; Sukalyani Banik; Sally V Catlett; Dennis W Metzger; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.